Production (Stage)
XORTX Therapeutics Inc.
XRTX.V
TSX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 16.21% | -23.05% | |||
| Depreciation & Amortization | -0.38% | 0.77% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 74.04% | -25.16% | |||
| Operating Income | -74.04% | 25.16% | |||
| Income Before Tax | -670.37% | 120.87% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -670.37% | 120.87% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -670.37% | 120.87% | |||
| EBIT | -74.04% | 25.16% | |||
| EBITDA | 3.79% | -36.22% | |||
| EPS Basic | -600.00% | 118.50% | |||
| Normalized Basic EPS | -599.15% | 118.51% | |||
| EPS Diluted | -609.38% | 118.45% | |||
| Normalized Diluted EPS | -599.15% | 118.51% | |||
| Average Basic Shares Outstanding | 14.08% | 12.82% | |||
| Average Diluted Shares Outstanding | 14.08% | 12.82% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||